ALMIRALL (E2Z BE) stock market data APIs
€12.9506
0(0%)
as of December 30, 2025
Try our APIs with
free plan!
ALMIRALL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for E2Z.BE.
Prev. Close
12.9506
Open
12.9506
High
12.9506
Low
12.9506
52 wk Range
7.9761-13.26
Market Cap
1 925 M
Dividends (Yield)
0.0198
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ALMIRALL data using free add-ons & libraries
Get ALMIRALL Fundamental Data
ALMIRALL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ALMIRALL News
New
Exploring Almirall’s (BME:ALM) Valuation Following Recent Share Price Strength
Almirall (BME:ALM) shares edged higher today, gaining just under 2%. This move has caught the attention of investors, who are keen to understand what might be driving sentiment for the Spanish pharmac...
Almirall SA (FRA:E2Z) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
This article first appeared on GuruFocus. Net Sales Growth: Nearly 13% year-on-year increase in the first nine months of 2025. Gross Margin: Moderated to 64.9% of sales, reflecting ongoing pressure r...
Almirall’s 2025 9M Results
Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress ...
United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall
Company Logo The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
